Sintilimab-Associated Psoriasis

Am J Ther. 2024 Jul-Aug;31(4):e504-e505. doi: 10.1097/MJT.0000000000001702.

Authors

Yi Wei^{1

2}, Mao Lin³, Rui-Ling Jia¹, Lu Cai¹, Bing-Jun Shi¹

Affiliations

¹ Department of Dermatology, Chongqing Hospital of Traditional Chinese Medicine (Chongqing Clinical Research Center for Dermatology; Chongqing Key Laboratory of Integrative Dermatology Research), Chongqing, P.R. China.
² ChengDu University of Traditional Chinese Medicine, Chengdu, P.R. China.
³ Department of Dermatology, West China Hospital, Sichuan University; Sichuan Province, P.R. China.

PMID: 38976540
DOI: 10.1097/MJT.0000000000001702

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Antibodies, Monoclonal, Humanized* / adverse effects
Humans
Middle Aged
Psoriasis* / chemically induced
Psoriasis* / drug therapy

Substances

Antibodies, Monoclonal, Humanized
sintilimab